Clarivate Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clarivate in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Clarivate stock.
View analyst ratings for Clarivate or view top-rated stocks.

Wall Street analysts have given Clarivate a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clarivate wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Clarivate saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 2,700,000 shares, an increase of 20.5% from the December 31st total of 2,240,000 shares. Based on an average trading volume of 1,470,000 shares, the short-interest ratio is presently 1.8 days.
View Clarivate's Short Interest.

Clarivate Plc (NYSE:CCC) announced its quarterly earnings data on Thursday, October, 29th. The industrial products company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by $0.01. The industrial products company had revenue of $284.40 million for the quarter, compared to the consensus estimate of $296.85 million. Clarivate had a positive trailing twelve-month return on equity of 7.92% and a negative net margin of 18.75%. The firm's revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.14 earnings per share.
View Clarivate's earnings history.

Clarivate's stock was trading at $20.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CCC shares have increased by 40.2% and is now trading at $28.94.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 1-year price targets for Clarivate's shares. Their forecasts range from $30.00 to $37.00. On average, they expect Clarivate's stock price to reach $33.67 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price.
View analysts' price targets for Clarivate or view top-rated stocks among Wall Street analysts.

Some companies that are related to Clarivate include LyondellBasell Industries (LYB), Westlake Chemical (WLK), Cabot (CBT), Kronos Worldwide (KRO), Koppers (KOP), Hawkins (HWKN), Tredegar (TG) and Trecora Resources (TREC).
View all of CCC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clarivate investors own include SodaStream International (SODA), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Ampio Pharmaceuticals (AMPE), Pfizer (PFE), Gilead Sciences (GILD), AbbVie (ABBV), Enterprise Products Partners (EPD), QUALCOMM (QCOM) and Antares Pharma (ATRS).

Clarivate trades on the New York Stock Exchange (NYSE) under the ticker symbol "CCC."

Clarivate's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.11%), Select Equity Group L.P. (6.16%), FMR LLC (5.21%), Bamco Inc. NY (1.07%), Bank of New York Mellon Corp (1.00%) and Janus Henderson Group PLC (1.00%).
View institutional ownership trends for Clarivate.

CCC stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Janus Henderson Group PLC, The Manufacturers Life Insurance Company , Lazard Asset Management LLC, Sei Investments Co., Kennedy Capital Management Inc., Bank of New York Mellon Corp, and Artemis Investment Management LLP.
View insider buying and selling activity for Clarivate or view top insider-selling stocks.

CCC stock was purchased by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Price T Rowe Associates Inc. MD, Amundi Pioneer Asset Management Inc., Clearbridge Investments LLC, William Blair Investment Management LLC, Arrow Capital Management LLC, BlackRock Inc., and FMR LLC.
View insider buying and selling activity for Clarivate or or view top insider-buying stocks.

Shares of CCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CCC stock can currently be purchased for approximately $28.94.

Clarivate has a market capitalization of $17.54 billion and generates $974.34 million in revenue each year. The industrial products company earns $-210,980,000.00 in net income (profit) each year or $0.35 on an earnings per share basis.

Clarivate employs 4,090 workers across the globe.

The following companies are subsidiares of Clarivate: CPA Global, Camelot Finance S.A., Camelot Holdings (Jersey) Limited, Camelot U.S. Acquisition 1 Co., Camelot U.S. Acquisition 2 Co., Camelot U.S. Acquisition 4 Co., Camelot U.S. Acquisition 5 Co., Camelot U.S. Acquisition 6 Co., Camelot U.S. Acquisition 7 Co., Camelot U.S. Acquisition LLC, Camelot UK Bidco Limited, Camelot UK Holdco Limited, Camelot UK Top Holdco Limited, Centre for Medicines Research International Limited, Clarivate Analytics (Belgium) N.V., Clarivate Analytics (Compumark) Inc., Clarivate Analytics (Deutschland) GmbH, Clarivate Analytics (Japan) Co. Ltd, Clarivate Analytics (UK) Limited, Clarivate Analytics (US) LLC, Clarivate Analytics Scientific Information Services (Beijing) Company Ltd., Darts-ip, Decision Resources Group, Kopernio, MarkMonitor Inc., Publons, TRCPL Projects Private Limited, and TrademarkVision.

Clarivate was founded in 2016.

The official website for Clarivate is clarivate.com.

Clarivate is headquartered at 1500 SPRING GARDEN STREET, PHILADELPHIA PA, 19130.

Clarivate's mailing address is 1500 SPRING GARDEN STREET, PHILADELPHIA PA, 19130. The industrial products company can be reached via phone at 215-386-0100 or via email at [email protected]